An open-label study of the effect of the addition of MabThera to standard chemotherapy on clinical response in patients with previously untreated mantle cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 29 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Planned End Date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 27 Aug 2012 Planned end date changed from 1 Jul 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.